Blog
Insights on clinical trial matching, evidence-informed ranking, and AI in healthcare
July 18, 2026
The best clinical trial for a patient increasingly doesn't have their cancer's name on it. Modern targeted therapies are tested in basket trials that enroll by a molecular target across many cancer types — so a search by cancer name walks right past them. This post explains how ClinTrialFinder matches by the molecule (on top of the usual diagnosis-based matching), how to recognize a basket trial in your results, and why the genuinely hard part isn't finding these trials but the tension between recall and precision.
Read more →
July 1, 2026
June 2026 updates: a new way to browse trials by mechanism (10 drug-class hubs — HER2 ADCs, TROP2 ADCs, KRAS inhibitors, CDK4/6, PARP, PSMA radioligand therapy, and the bispecific families — plus a /mechanisms catalog), 12 new drug pages (the catalog more than doubled), patient-focused ASCO 2026 coverage, a much faster wizard (the first step went from ~20 seconds to near-instant), and a batch of matching-accuracy fixes.
Read more →
June 9, 2026 • Post-conference synthesis
ASCO 2026 (June 5–9, Chicago) closed today. Seven patient-relevant takeaways: (1) pan-RAS goes prime time with daraxonrasib in two Phase 3s at once (RASolve 301 NSCLC + RASolute 304 adjuvant PDAC); (2) ivonescimab keeps stacking 1L Phase 3 readouts (HARMONi-7) and moves into TNBC, biliary, and colorectal; (3) T-DXd + pertuzumab is the new HER2+ MBC frontline standard after DESTINY-Breast09 and the Dec 2025 FDA approval; (4) HER3-DXd (patritumab deruxtecan) reaches registrational Phase 3 in breast (HERTHENA-Breast03); (5) tarlatamab matures from salvage into maintenance, SubQ, and EP-NEC + brain expansion; (6) cadonilimab (PD-1/CTLA-4) and rilvegostomig (PD-1/TIGIT) bispecifics continue global Phase 3 expansion; (7) the personalized mRNA cancer vaccine V940 (intismeran) reaches Phase 3 in adjuvant resected NSCLC (INTerpath-002). 32 NCT citations.
Read more →
June 1, 2026
May 2026 updates: 10 trial landscape pages for browse-before-you-search, 8 new drug pages (T-DXd, ivonescimab, cadonilimab, rilvegostomig, patritumab deruxtecan, daraxonrasib, ADI-PEG 20, tarlatamab), one-click prefill from cancer page to wizard, a faster treatment-history step that leads with line-of-therapy, and four ASCO 2026 patient previews.
Read more →
May 5, 2026
Five April improvements: per-trial detail pages with eligibility breakdowns, confidence tiers and surfacing reasons that explain why each match, faster searches (NPC dropped from 23 minutes to 13 minutes), wider coverage by expanding cancer-name synonyms, and a smoother wizard.
Read more →
March 30, 2026
Four improvements this month: search results now arrive in 5–15 minutes, non-treatment studies are filtered out more accurately, cross-cancer drug signals inform ranking, and remission status is recognized to prevent irrelevant matches.
Read more →
March 15, 2026
No more blank text boxes. ClinTrialFinder now walks you through clinical trial matching step by step—asking the right questions for your specific disease, showing relevant treatment options and biomarkers, and adapting the number of steps based on your condition. No medical knowledge required.
Read more →
March 6, 2026
You open a trial matching tool and see a text box: "Describe your condition." What do you write? This guide breaks down exactly what information helps—cancer type, stage, prior treatments, biomarkers—and what you can skip.
Read more →
March 3, 2026
Most clinical trial matching tools stop at relevance and eligibility screening. We tested a real cancer patient case and found that TrialGPT-only ranking would have shown the wrong trials first—including a diagnostic imaging study ranked #1. Evidence-informed ranking correctly identified novel therapies as the best options.
Read more →
